Security Snapshot

Century Therapeutics, Inc. - Common Stock, par value $0.0001 per share (IPSC) Institutional Ownership

CUSIP: 15673T100

13F Institutional Holders and Ownership History from Q2 2021 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

42

Shares (Excl. Options)

37.92MFull value: 37,916,102 · shares · 30 Sep 2026

Price

$1.71

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+1,627,481
Value change
+$2,262,813
Number of holders
42
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
180,747,818
SEC-reported price per share
$1.38
Insider filing price
$1.38
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • IPSC - Century Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 15673T100.
  • 42 institutions reported positions in Q3 2026.
  • 9 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 101 to 42 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $387.02MFull value: $387,019,087 · USD · 30 Jun 2026
    to
    $64.82MFull value: $64,817,460 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 42 institutions filings for Q3 2026.

Open SEC evidence

Security key

15673T100

13F reference period

Q3 2026

13F holders

42

13D/G owners

9

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
9
Security
IPSC
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 9.9% $16,997,172 17,944,649 RA Capital Management, L.P. 09 Jan 2026
TCG Crossover GP II, LLC 9.9% $15,978,987 17,754,430 Chen Yu 09 Jan 2026
Deep Track Capital, LP 7.3% $12,137,760 13,486,400 Deep Track Capital, LP 08 Jan 2026
Venrock Healthcare Capital Partners III, L.P. 7.1% +48% $12,354,782 +$8,606,536 13,043,478 +230% Venrock Healthcare Capital Partners III, L.P. 09 Jan 2026
RTW INVESTMENTS, LP 7.1% $29,608,695 13,043,478 RTW Investments, LP 31 Mar 2026
Commodore Capital LP 7.1% $12,354,782 13,043,478 Commodore Capital LP 09 Jan 2026
Point72 Asset Management, L.P. 3.3% -50% $13,539,819 +$7,071 5,964,678 +0.05% Point72 Asset Management, L.P. 31 Mar 2026
Bain Capital Life Sciences Opportunities III, LP 4.1% $1,762,227 3,538,609 Bain Capital Life Sciences Opportunities III, LP 30 Sep 2025
Casdin Capital, LLC 3.7% $1,702,527 3,212,316 Casdin Capital, LLC 31 Mar 2025
As of 30 Sep 2026, 42 institutional investors reported holding
37.92MFull value: 37,916,102 · shares · 30 Sep 2026
shares of Century Therapeutics, Inc. - Common Stock, par value $0.0001 per share (IPSC). This represents 21% of the company’s total
180.75MFull value: 180,747,818 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
31%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Versant Venture Management, LLC 6.7% 12,166,109 0% 19% $20,804,046
Deep Track Capital, LP 5.2% 9,462,645 0% 0.27% $16,181,123
RTW INVESTMENTS, LP 4.8% 8,695,652 0% 0.15% $14,869,565
VANGUARD CAPITAL MANAGEMENT LLC 3.1% 5,692,587 -0.19% 0% $9,734,324
Woodline Partners LP 3.1% 5,663,346 +33% 0.03% $9,684,321
Spruce Street Capital LP 2.2% 4,059,054 0% 1.1% $6,940,982
GEODE CAPITAL MANAGEMENT, LLC 1.6% 2,870,994 -3.6% 0% $4,910,631
STATE STREET CORP 1.4% 2,513,350 +36% 0% $4,297,829
RENAISSANCE TECHNOLOGIES LLC 0.59% 1,074,200 -15% 0% $1,836,882
VANGUARD PORTFOLIO MANAGEMENT LLC 0.57% 1,035,026 +1.9% 0% $1,769,894
VANGUARD FIDUCIARY TRUST CO 0.41% 737,585 +0.01% 0% $1,261,270
Invesco Ltd. 0.22% 403,214 +5.7% 0% $689,496
DIMENSIONAL FUND ADVISORS LP 0.18% 318,535 +17% 0% $544,041
AMERICAN CENTURY COMPANIES INC 0.13% 232,301 +33% 0% $397,235
MORGAN STANLEY 0.08% 144,719 +276% 0% $247,469
Spark Investment Management LLC 0.07% 128,200 +117% 0.35% $219,222
Integrated Quantitative Investments LLC 0.07% 127,927 0.04% $218,755
DEUTSCHE BANK AG\ 0.06% 105,095 -13% 0% $179,712
BANK OF AMERICA CORP /DE/ 0.06% 101,113 -36% 0% $172,903
RAYMOND JAMES FINANCIAL INC 0.05% 91,323 0% 0% $156,162
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC 0.04% 78,186 +0.46% 0% $114,151
TEMA ETFS LLC 0.03% 59,274 0% $101,359
Tidal Investments LLC 0.03% 59,274 0% $101,359
MetLife Investment Management, LLC 0.03% 55,061 -28% 0% $94,154
XTX Topco Ltd 0.03% 51,900 0% $88,749

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
22
Headline period
Q3 2026
Rows shown
1-22 of 22
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 37,916,102 $64,817,460 +$2,262,813 $1.71 42
2026 Q2 158,016,283 $387,019,087 +$47,482,242 $2.45 101
2026 Q1 138,751,378 $312,461,788 +$246,781,319 $2.26 72
2025 Q4 25,712,702 $25,569,840 +$6,410,887 $0.99 46
2025 Q3 20,280,322 $10,103,490 -$1,188,475 $0.50 53
2025 Q2 22,628,192 $12,642,486 -$3,582,180 $0.56 64
2025 Q1 29,565,044 $14,071,235 -$4,277,613 $0.48 69
2024 Q4 36,396,514 $36,761,199 -$7,768,598 $1.01 70
2024 Q3 39,649,193 $67,797,499 -$1,211,276 $1.71 66
2024 Q2 40,117,934 $102,301,880 +$40,961,743 $2.55 59
2024 Q1 23,113,173 $96,605,177 +$22,882,584 $4.18 66
2023 Q4 17,675,436 $58,683,678 -$543,594 $3.32 60
2023 Q3 18,060,757 $36,118,983 -$2,770,150 $2.00 53
2023 Q2 19,290,007 $60,957,915 -$2,350,461 $3.16 62
2023 Q1 20,016,851 $69,456,630 -$4,620,580 $3.47 63
2022 Q4 20,893,156 $107,178,277 -$3,631,215 $5.13 65
2022 Q3 21,098,040 $208,661,435 -$4,940,964 $9.89 52
2022 Q2 21,756,667 $182,752,181 -$3,241,178 $8.40 51
2022 Q1 22,151,698 $278,859,136 +$11,504,710 $12.59 51
2021 Q4 21,137,514 $335,200,000 +$24,348,825 $15.86 50
2021 Q3 19,798,633 $496,205,288 +$62,122,502 $25.16 47
2021 Q2 16,881,896 $490,834,435 +$490,834,432 $29.34 35
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .